Cannabis-Tobacco Co-Use Treatment Study

The purpose of the RECLAIM study is to evaluate the effectiveness of varenicline (sometimes known as Chantix) compared to placebo (an inactive substance) for the treatment of cigarettes and cannabis (marijuana). Varenicline is not FDA approved for the combination treatment of cigarette abstinence and cannabis reduction or abstinence. All participants will also receive counseling and access to online treatment modules during a quit attempt for cigarettes and a reduction attempt for cannabis. This study is being conducted by the Medical University of South Carolina. All procedures are conducted remotely and there is no in-person visits are needed. To qualify, participants must be 18 or older, live in South Carolina, use cigarettes and cannabis, and are interested in quitting cigarettes and reducing cannabis.

NCT Number	NCT06883162
Lead Sponsor	Medical University of South Carolina Collaborators: National Cancer Institute (NCI)
Conditions	Tobacco Use Disorder, Tobacco Use Cessation, Cannabis Use, Cannabis Use Disorder, Marijuana Use
Enrollment	200 participants
Start Date	2025-05-06
Primary Completion	2028-09-01 (estimated)
Study Completion	2029-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-03